Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four AncestriesSummary
Background & Aims: Observational studies have linked lipid-lowering drug targets pro-protein convertase subtilisin/kexin 9 (PCSK9) and HMG-CoA reductase (HMGCR) with adverse liver outcomes; however, liver disease incidence varies across diverse populations, and the long-term hepatic impact o...
Main Authors: | Daniel B. Rosoff, Andrew S. Bell, Josephin Wagner, Lucas A. Mavromatis, Ali Hamandi, Lauren Park, Jeesun Jung, Falk W. Lohoff |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Cellular and Molecular Gastroenterology and Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352345X23001637 |
Similar Items
-
Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
by: Sehoon Park, et al.
Published: (2023-07-01) -
Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01) -
Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug‐Target Mendelian Randomization Study
by: Andrew S. Bell, et al.
Published: (2022-11-01) -
Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01) -
PCSK9 inhibition and broad health outcomes: A Mendelian randomization phenome‑wide association study
by: Kai Zhang, et al.
Published: (2024-05-01)